Oncology drug sales
reps can sharpen in-office visits with doctors with specific actions. That’s
according to a ZoomRx study of in-office oncology promotions across 120 brands
during the past five years.
The findings?
New information, short visits and visual aids resulted in more impactful
visits. For instance, visits where sales reps delivered novel data or
information were considered “highly impactful” by 40% of oncologists versus
just 24% when no new information was presented, the digital health consultancy
found. That’s an opportunity for reps. because only one-fifth of visits contain
new information, according to ZoomRx’s surveyed oncologists.